Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice

INTRODUCTION: Current treatments for psychosis in Alzheimer's disease (AD), a syndrome characterized by more rapid deterioration and reduced synaptic protein abundance relative to non‐psychotic AD, are inadequate. Fingolimod, a currently US Food and Drug Administration (FDA)–approved pharmacoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Krivinko, Josh M., Erickson, Susan L., MacDonald, Matthew L., Garver, Megan E., Sweet, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395154/
https://www.ncbi.nlm.nih.gov/pubmed/36016832
http://dx.doi.org/10.1002/trc2.12324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395154/
https://www.ncbi.nlm.nih.gov/pubmed/36016832
http://dx.doi.org/10.1002/trc2.12324

Ejemplares similares